Sentry Investment Management LLC Acquires 134 Shares of Stryker Co. (NYSE:SYK)

Sentry Investment Management LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 9.1% during the third quarter, HoldingsChannel reports. The firm owned 1,605 shares of the medical technology company’s stock after acquiring an additional 134 shares during the quarter. Sentry Investment Management LLC’s holdings in Stryker were worth $580,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SYK. Centennial Bank AR raised its holdings in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after buying an additional 48 shares during the period. Central Pacific Bank Trust Division bought a new stake in shares of Stryker during the first quarter worth $39,000. HBW Advisory Services LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. Grove Bank & Trust lifted its position in Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares in the last quarter. Finally, DT Investment Partners LLC boosted its stake in Stryker by 114.3% in the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 72 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $366.90 on Tuesday. The firm has a market capitalization of $139.87 billion, a PE ratio of 39.32, a PEG ratio of 2.77 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The company’s 50-day moving average is $360.43 and its 200-day moving average is $344.64. Stryker Co. has a fifty-two week low of $266.93 and a fifty-two week high of $374.63.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the business posted $2.46 earnings per share. Equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.80 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s payout ratio is presently 34.30%.

Wall Street Analyst Weigh In

Several analysts have issued reports on SYK shares. UBS Group lifted their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their target price on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Evercore ISI raised their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird increased their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,068 shares of company stock valued at $3,693,972. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.